-
公开(公告)号：US20210155606A1
公开(公告)日：2021-05-27
申请号：US17170690
申请日：2021-02-08
申请人： NOVARTIS AG
发明人： Luca ARISTA , Sreehari BABU , Jianwei BIAN , Kai CUI , Michael Patrick DILLON , Rene LATTMANN , Jialiang LI , Lv LIAO , Dimitrios LIZOS , Rita RAMOS , Nikolaus Johannes STIEFL , Thomas ULLRICH , Peggy USSELMANN , Xiaoyang WANG , Liladhar Murlidhar WAYKOLE , Sven WEILER , Yubo ZHANG , Yizong ZHOU , Tingying ZHU
IPC分类号： C07D401/14 , C07D405/14 , C07D401/10 , C07D401/12 , C07D409/14 , C07D213/82 , C07D411/14 , C07D491/107 , A61P19/00 , C07D417/00 , C07D413/00 , C07D419/00 , A61P19/08 , C07D413/10 , C07D413/12 , C07D413/14 , C07D491/20
摘要： The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
-
公开(公告)号：US20190062283A1
公开(公告)日：2019-02-28
申请号：US16056881
申请日：2018-08-07
申请人： NOVARTIS AG
发明人： Donatella CHIANELLI , Runyan LI , Valentina Molteni , John Nelson , Jason Thomas Roland , Paul Vincent Rucker , David Charles Tully , Xiaoyang WANG , Liladhar Murlidhar WAYKOLE , Yubo ZHANG , Bo ZHOU
IPC分类号： C07D231/54 , A61K31/4745 , A61K31/4439 , A61K31/4162 , C07D471/04 , C07D471/06 , C07D491/052 , A61K31/416
摘要： The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
-
公开(公告)号：US20210253534A1
公开(公告)日：2021-08-19
申请号：US17236596
申请日：2021-04-21
申请人： NOVARTIS AG
发明人： Donatella CHIANELLI , Runyan LI , Valentina MOLTENI , John NELSON , Jason Thomas ROLAND , Paul Vincent RUCKER , David Charles TULLY , Xiaoyang WANG , Liladhar Murlidhar WAYKOLE , Yubo ZHANG , Bo ZHOU
IPC分类号： C07D231/54 , C07D471/04 , C07D491/052 , A61K31/416 , A61K31/4162 , A61K31/4439 , A61K31/4745 , C07D471/06
摘要： The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
-
公开(公告)号：US20190211022A1
公开(公告)日：2019-07-11
申请号：US16311638
申请日：2017-06-19
申请人： NOVARTIS AG
发明人： Ying HUANG , Bo LIU , Liang MAO , Long WANG , Liladhar Murlidhar WAYKOLE , Lijun ZHANG
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P35/02
CPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P35/02 , C07B2200/13
摘要： Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.
-
公开(公告)号：US20200299265A1
公开(公告)日：2020-09-24
申请号：US16884666
申请日：2020-05-27
申请人： NOVARTIS AG
发明人： Luca ARISTA , Sreehari BABU , Jianwei BIAN , Kai CUI , Michael Patrick DILLON , Rene LATTMANN , Jialiang LI , Lv LIAO , Dimitrios LIZOS , Rita RAMOS , Nikolaus Johannes STIEFL , Thomas ULLRICH , Peggy USSELMANN , Xiaoyang WANG , Liladhar Murlidhar WAYKOLE , Sven WEILER , Yubo ZHANG , Yizong ZHOU , Tingying ZHU
IPC分类号： C07D401/14 , C07D405/14 , C07D401/10 , C07D401/12 , C07D409/14 , C07D213/82 , C07D411/14 , C07D491/107 , A61P19/00 , C07D417/00 , C07D413/00 , C07D419/00 , A61P19/08 , C07D413/10 , C07D413/12 , C07D413/14 , C07D491/20
摘要： The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
-
公开(公告)号：US20200247757A1
公开(公告)日：2020-08-06
申请号：US16854762
申请日：2020-04-21
申请人： NOVARTIS AG
发明人： Donatella CHIANELLI , Runyan LI , Valentina MOLTENI , John NELSON , Jason Thomas ROLAND , Paul Vincent RUCKER , David Charles TULLY , Xiaoyang WANG , Liladhar Murlidhar WAYKOLE , Yubo ZHANG , Bo ZHOU
IPC分类号： C07D231/54 , C07D471/04 , C07D491/052 , A61K31/416 , A61K31/4162 , A61K31/4439 , A61K31/4745 , C07D471/06
摘要： The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
-
公开(公告)号：US20190161474A1
公开(公告)日：2019-05-30
申请号：US16318250
申请日：2017-07-18
申请人： NOVARTIS AG
发明人： Luca ARISTA , Sreehari BABU , Jianwei BIAN , Kai CUI , Michael Patrick DILLON , Rene LATTMANN , Jialiang LI , Lv LIAO , Dimitrios LIZOS , Rita RAMOS , Nikolaus Johannes STIEFL , Thomas ULLRICH , Peggy USSELMANN , Xiaoyang WANG , Liladhar Murlidhar WAYKOLE , Sven WEILER , Yubo ZHANG , Yizong ZHOU , Tingying ZHU
IPC分类号： C07D401/14 , C07D401/10 , C07D401/12 , C07D491/20 , C07D405/14 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , A61P19/08
摘要： The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.014 秒)
